摘要
目的:比较TP方案与NP方案治疗晚期乳腺癌的临床疗效和不良反应。方法:60例晚期乳腺癌患者随机分成TP方案组(30例)和NP方案组(30例)。TP方案:紫杉醇75mg/m2,持续静脉滴入3h,d1、d8和d15;DDP30mg/m2,静脉滴入,d1～d3。NP方案:NVB30mg/m2,静脉推注,d1、d8;DDP30mg/m2,静脉滴入,d1～d3。上述2个方案,每4周为1个疗程。结果:TP方案的总有效率为50%(15/30),中位疾病进展时间(TTP)为8.1个月,中位生存时间为16个月,1年生存率为56.7%(17/30);NP方案的总有效率为46.7%(14/30),中位疾病进展时间(TTP)为6.9个月,中位生存时间为15.0个月,1年生存率为43.3%(13/30)。两组方案的主要不良反应为骨髓抑制及胃肠道反应。结论:两组方案对晚期乳腺癌患者均有较好疗效,不良反应可耐受,近期疗效无明显差异。
Objective： To observe the efficacy and toxicity of paclitaxcl and cisplatin（TP regime） versus navelbine cisplatin （NP regime） in the treatment of advanced breast cancer. Methods： 60 cases with advanced breast cancer were randomly divided into TP programme（30 cases） and NP programme（30 cases）. 60 cases were treated with vinorelbine（NVB 30 mg/m^2,on days 1,8） plus cisplatin（DDP 30 mg/m^2 on days 1,2,3） or paclitaxel（75 mg/m^2 on days 1,8,15） plus cisplatin （30 mg/m^2 on day 1,2,3） every 4 weeks. Analysis were done by intention to treat. Results： For TP regiment： the total effective rate was 50%（15/30）,TYP was 8.1 months,the median survival time was 16 months, and the rate of survival in one year was 56.7% （17/30）.For NP regiment： the total effective rate of was 40.0%（12/30）,TTP was 6.9 months,the median survival time was 15 months,and the rate of survival in one year was 43.3%（13/30）.The main adverse drug reactions of two regiments were restraint of marrow and gastrointestinal reactions. Conclusion： Combination of NP and TP has good therapeutic effect for patients with anthracycline-resistant ABC. And the toxic reponses is tolerable. There is no significant difference between objective responses of two regimens.
出处
《中国医药导报》
CAS
2008年第36期41-42,共2页
China Medical Herald
关键词
乳腺肿瘤
紫杉醇
长春瑞滨
顺铂
化疗
Mammary carcinoma
Paclitaxel
Vinorelbine tartrate
Cisplatin
Chemotherapy
